• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

Recce Pharmaceuticals to Receive Australian Grant

Like 0

By Mahlia Stewart, Tuesday, 10 January 2023

Recce receives a grant intent from the Australian Patent Office for an antivirus agent targeting mega bugs coronavirus, SARS, and HIV, growing in big pharmaceutical markets across the world.

Reporting from Sydney, drug discovery and development business Recce Pharmaceuticals [ASX:RCE] released the news that it’s now received a grant intent from the Australian Patent Office.

The grant is for an antivirus agent, Patent Family 3 ‘Anti-Virus Agent and Method for Treatment of Viral Infection’, which targets a range of viruses, including SARS-CoV-2, coronaviruses, influenza, and HIV.

RCE’s stock price was climbing close to 5% by the early afternoon, pulling the stock’s share value up 3% for the first week of the year.

However, the biotech remains in the red over the past full year, having slumped more than 40% throughout 2022.

Versus the ASX 200 average over the 12 months, RCE underperformed by 36%.

ASX:RCE stock chart 2023 reece

Source: TradingView

Grant intent awarded to Recce as Australian Patent

The virus drug developer announced a grant intent from the Australian Patent Office for its antivirus agent development in Australia — Recce’s Patent Family 3 ‘Anti-Virus Agent and Method for Treatment of Viral Infection’.

RCE has been developing as a business, commercialising new classes of synthetic antibiotics on a spectrum of activity, focused mostly on designing the combative qualities for antibiotic resistance to superbugs and overall addressing the growing global health challenge as newer, stronger variants emerge and threaten the global population.

Recce claims its latest product RECCE® 327 (R327) and Anti-Viral formulation RECCE® 529 (R529), can be used to treat viruses with a lipid envelope or coat, examples being SARS-CoV-2, coronaviruses, influenza viruses, HIV, Hepatitis, Ross River, and Herpes viruses.

Treatment can be administered for either R327 or R529 as an oral medicine, injection, inhalation, or even transdermal dose application — applied to the skin as an adhesive patch for slow body absorption.

The company said this is its final patent, following grants in the largest pharmaceutical markets across the globe, including China, Hong Kong, Japan, and Europe.

Chief Executive Officer James Graham stated:

‘Receiving notice that this Australian patent application will proceed to grant is another milestone in the Company’s global IP strategy; and are thrilled by the yet further validation to the potential importance of our infectious disease compounds.’

Recce’s journey in anti-infective research

At the end of 2022, Reece announced it had begun a new research collaboration agreement with Murdoch Children’s Research Institute for its Anti-Infective Research (AIR) Unit, which included the procurement of infectious disease experts, laboratory space access, and a library of clinical isolates and drug-resistant pathogens.

Together, Murdoch Children’s and Former Head of Murdoch Children’s Mucosal Immunology and Recce’s Vice President of Translational Sciences, Dr Phil Sutton, continue to develop solutions to a range of deadly pathogens.

Recce’s pipeline includes R327 Intravenous for serious bacterial infections, sepsis, and urinary tract, while R327 Topical targets wounds, burns, and ulcers that have either reached or are midway through Phase 2.

In September 2022, the company ended the quarter with a cash balance of $5.73 million, with cash outflows of $5.86 million.

It’s usual for research and development expenses to outweigh cash inflows as companies gain access to growing medical markets. As seen today, RCE is taking a step closer to meeting such targets.

Five bargain stocks

The end of 2022 and the beginning of FY23 were fraught with challenges.

With some effects of the pandemic still lingering, we were handed an influx of new challenges — inflation, war, continually rising rates…

The hard yards aren’t quite over yet, which is why everyone is looking to save a pretty penny where they can.

And it’s in times like these that some real ASX stock bargains can emerge — if you know where to look.

Our small caps expert Callum Newman has done the hard work for you.

He’s found five of what he calls ‘the best stocks to own in Australia’ right now.

And the best part is, right now, they don’t even cost that much.

Click here to discover Callum’s top five Aussie bargain stocks.

 

Regards,

Mahlia Stewart,

For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Mahlia Stewart

Mahlia’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Your best chance to be in the top 10% will come from here
    By Callum Newman

    Oil was a big macro influencer fifty years ago. The OPEC embargo shook even mighty America for a moment in time. But it’s not 1973 anymore. I have a better idea.

  • How the AI explosion will perfectly offset the demographic implosion
    By Nick Hubble

    Half the population is terrified of demographic decline. The other half is horrified about AI. The two need to take a long hard look at each other.

  • Oil price threat to the market: a fizzer…so far
    By Callum Newman

    The market usually doesn’t sell off in a big way when we get the kind of geopolitical flashpoint we’re seeing now. However, I must admit I still expected the Aussie market to be down at least a little bit this morning. As I write, it’s mildly green. Are investors being too complacent here?

Primary Sidebar

Latest Articles

  • Your best chance to be in the top 10% will come from here
  • How the AI explosion will perfectly offset the demographic implosion
  • Oil price threat to the market: a fizzer…so far
  • Ford Shuts Its Doors as Rare Earth Grip Tightens
  • China’s Game of Commodity Chicken

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988